title: Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control.
abstract: OBJECTIVE
  This observational study evaluated the behavior and outcome of cutaneous breast cancer metastasis treated with eribulin.
  
  
  METHODS
  From November 2012 to January 2013, oncologists completed a database with patient, tumor and treatment characteristics from 14 Italian cancer centers. Skin lesions were assessed by Response Evaluation Criteria In Solid Tumors and cutaneous symptoms by present/absent criteria.
  
  
  RESULTS
  A total of 23 metastatic breast cancer patients with skin metastasis who were treated with eribulin were analyzed. After treatment, 43% of patients exhibited a partial response, 35% stable disease and 22% progressive disease. Regarding only the skin response, 26% obtained a complete response, 22% a partial response, 39% stable disease and 13% progressive disease. We found an improvement in symptoms, infiltration and ulceration. With a median follow-up of 6 months, median progression-free survival was 4.3 months and median overall survival was 9.1 months.
  
  
  CONCLUSIONS
  The response rate of skin metastasis to eribulin treatment was coherent with systemic responses. The good clinical response in most patients reflected symptom improvement.
authors.affiliation: Department of Oncology, AO Fatebenefratelli e Oftalmico, Corso di Porta Nuova, 23, Milan, Italy.
authors.forename: Nicla
authors.initials: N
authors.lastname: La Verde
authors.forename: Anna
authors.initials: A
authors.lastname: Moretti
authors.forename: Gabriella
authors.initials: G
authors.lastname: Farina
authors.forename: Maria Chiara
authors.initials: MC
authors.lastname: Dazzani
authors.forename: Teresa
authors.initials: T
authors.lastname: Gamucci
authors.forename: Karen
authors.initials: K
authors.lastname: Borgonovo
authors.forename: Mario
authors.initials: M
authors.lastname: Botta
authors.forename: Nello
authors.initials: N
authors.lastname: Salesi
authors.forename: Monica
authors.initials: M
authors.lastname: Zuradelli
authors.forename: Ida
authors.initials: I
authors.lastname: Pavese
authors.forename: Elena
authors.initials: E
authors.lastname: Barbieri
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Cretella
authors.forename: Tiziana
authors.initials: T
authors.lastname: Saladino
authors.forename: Paola
authors.initials: P
authors.lastname: Varese
authors.forename: Elena Silvia
authors.initials: ES
authors.lastname: Traverso
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Addamo
authors.forename: Mariangela
authors.initials: M
authors.lastname: Ciccarese
authors.forename: Anna Iolanda
authors.initials: AI
authors.lastname: Rispoli
authors.forename: Arianna
authors.initials: A
authors.lastname: Pellegrino
authors.forename: Lucia
authors.initials: L
authors.lastname: Mentuccia
authors.forename: Serena
authors.initials: S
authors.lastname: Girelli
authors.forename: Sheila
authors.initials: S
authors.lastname: Piva
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Maio
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005663:Furans / Q000008:administration & dosage*; D006801:Humans; D007659:Ketones / Q000008:administration & dosage*; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D000095662:Polyether Polyketides
chemical_list: D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides